Jason Karlawish

speaker

1,378 appearances 5 recordings 1 series first heard Feb 2021 last heard Dec 2023

Jason Karlawish’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

No recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.

newest first · ▶ plays the moment

need to make that decision.

Obviously I'm there I want to help them make it.

I think that's why geriatricians again should be part of this because we're good at talking to our patients and listening.

Um but it does make for a complicated decision.

Uh it does.

This is not a risk-free drug and for people who are Apo E4 carriers it's a particularly problematic uh decision.

If a homozygo patient wants to take it, I would prescribe it.

But I think they need to understand that they're gonna need careful monitoring for risk.

They and I may not be able to catch that risk before it becomes symptomatic and causes some problems with gait and falls, et cetera.

But again, I I would view that as their choice.

That's right.

There was this patient in the study

uh who died and then a patient in the open label study who died.

Both of them in the context

Of getting ill.

And you know, it's kinda like the it gets a little frustrating when you hear like did Lacanab cause their death or not?

As we all know in geriatrics idea of what causes death in patients with multiple problems.

It's quite clear though that exposure to liquinomat contributed to their death.

I mean, it increases the risk of brain bleeds, and these people are getting blood thinners, one for a stroke and the other for a heart attack.

And so yeah, that probably was not a good combination.

Showing 661–680 of 1,378 · page 34 of 69